Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in an upcoming investor conference. The company's management will be present at the Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET.
A live webcast of the event will be available, along with up-to-date details and an archived replay, on the 'Events and Presentations' page in the 'Investors' section of Avidity's website. Interested parties can access this information at https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), una compagnia biofarmaceutica che sviluppa Coniugati di Oligonucleotidi Anticorpali (AOCs™), ha annunciato la sua partecipazione a una prossima conferenza per investitori. La direzione dell'azienda sarà presente al 8° Congresso Annuale sui Medicinali Genetici di Chardan il 1 ottobre alle 7:30 a.m. PT / 10:30 a.m. ET.
Una diretta web dell'evento sarà disponibile, insieme a dettagli aggiornati e a una registrazione archiviata, nella pagina 'Eventi e Presentazioni' nella sezione 'Investitori' del sito web di Avidity. Le parti interessate possono accedere a queste informazioni su https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), una empresa biofarmacéutica que desarrolla Conjugados de Oligonucleótidos de Anticuerpos (AOCs™), ha anunciado su participación en una próxima conferencia para inversores. La dirección de la empresa estará presente en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan el 1 de octubre a las 7:30 a.m. PT / 10:30 a.m. ET.
Se dispondrá de una transmisión en vivo del evento, junto con detalles actualizados y una repetición archivada, en la página 'Eventos y Presentaciones' en la sección 'Inversores' del sitio web de Avidity. Las partes interesadas pueden acceder a esta información en https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), 항체 올리고뉴클레오타이드 접합체(AOCs™)를 개발하는 생명공학 회사는 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 경영진은 Chardan 제8회 유전자 의약품 콘퍼런스에 10월 1일 오전 7:30 PT / 오전 10:30 ET에 참석합니다.
이벤트의 실시간 웹캐스트는 '투자자' 섹션의 '이벤트 및 프레젠테이션' 페이지에서 최신 세부정보와 보관 replay와 함께 제공됩니다. 관심 있는 분들은 https://aviditybiosciences.investorroom.com/events-and-presentations에서 이 정보를 확인할 수 있습니다.
Avidity Biosciences (Nasdaq: RNA), une entreprise biopharmaceutique développant des Conjugués d'Oligonucléotides Anticorps (AOCs™), a annoncé sa participation à une prochaine conférence pour investisseurs. La direction de l'entreprise sera présente à la 8e Conférence Annuelle sur les Médicaments Génétiques de Chardan le 1er octobre à 7h30 PT / 10h30 ET.
Une diffusion en direct de l'événement sera disponible, ainsi que des détails mis à jour et une rediffusion archivée, sur la page 'Événements et Présentations' dans la section 'Investisseurs' du site web d'Avidity. Les parties intéressées peuvent accéder à ces informations à l'adresse suivante : https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences (Nasdaq: RNA), ein biopharmazeutisches Unternehmen, das Antikörper-Oligonukleotid-Konjugate (AOCs™) entwickelt, gab seine Teilnahme an einer bevorstehenden Investorenkonferenz bekannt. Das Management des Unternehmens wird am 8. Chardan-Jahreskongress für Genmedikamente am 1. Oktober um 7:30 Uhr PT / 10:30 Uhr ET teilnehmen.
Eine Live-Übertragung der Veranstaltung wird verfügbar sein, zusammen mit aktuellen Details und einer archivierten Wiederholung, auf der Seite 'Veranstaltungen und Präsentationen' im Bereich 'Investoren' der Website von Avidity. Interessierte Parteien können diese Informationen unter https://aviditybiosciences.investorroom.com/events-and-presentations abrufen.
- None.
- None.
- Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET
A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in
Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302257800.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) participating in the Chardan Genetic Medicines Conference?
Where can I find the webcast for Avidity Biosciences' (RNA) presentation at the Chardan conference?
What type of RNA therapeutics is Avidity Biosciences (RNA) developing?
What is the stock symbol for Avidity Biosciences?
